amikacin

Amikacin (Amikacina) is a broad-spectrum antibiotic derived from kanamycin.

Amikacin hydrate (BAY 41-6551 hydrate) is an aminoglycoside antibiotic with bacteriostatic activity used in studies of drug-resistant Mycobacterium tuberculosis infections and Gram-negative bacterial infections, and is commonly used in the clinic for urinary tract infections caused by E. coli.

Amikacin sulfate is a broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and ototoxic like the other aminoglycoside antibiotics.

Amikacin disulfate (BAY-416651 sulfate) is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A.

Amikacin impurity 2 (compound Impurity VI) is an impurity found in Amikacin sulfate.

Amikacin-D5 is a deuterated compound of Amikacin. Amikacin (T1013) has a CAS number of 37517-28-5. Amikacin (T1013) is a broad-spectrum antibiotic derived from kanamycin.

Amikacin-[D5] Hydrochloride (Standard) is a reference standard of Amikacin-[D5] Hydrochloride intended for quantitative analysis, quality control, and related biochemical research applications.

Protosappanin A (PTA) has anti-oxidative/nitrative activities on brain immune and neuroinflammation through regulation of CD14/TLR4-dependent IKK/IκB/NF-κB inflammation signal pathway; it exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Protosappanin A induces immunosuppression of rats heart transplantation targeting T cells in grafts via NF-kappaB pathway. Protosappanin A and protosappanin B have antimicrobial activity, they show both alone activities and resistance reversal effects of amikacin and gentamicin against MRSA. Protosappanin A shows strong effect against HIV-1 IN with an IC50 value of 12.6 uM.